Form 4: Moderna President Stephen Hoge Reports Routine Stock Acquisitions and Tax-Related Sales

Moderna President Stephen Hoge reported the acquisition of common stock through restricted stock unit vesting and subsequent sales to cover tax obligations.

Summary

• Stephen Hoge, President of Moderna, Inc. (MRNA), reported changes in his beneficial ownership of company common stock.
• On May 27, 2025, Mr. Hoge acquired 1,436 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently on May 27, 2025, 695 shares were disposed of at a price of $26.26 per share to satisfy tax withholding obligations related to the RSU vesting.
• On May 28, 2025, an additional 610 shares of common stock were acquired due to RSU vesting.
• On May 28, 2025, 295 shares were disposed of at a price of $26.76 per share to cover tax withholding obligations for the second RSU vesting event.
• Following these transactions, Mr. Hoge directly beneficially owns 1,451,783 shares of common stock.
• He also indirectly owns 4,116 shares through Valhalla, LLC, and 151,933 shares through a trust for the benefit of his spouse and children.
• Remaining derivative holdings include 15,805 Restricted Stock Units after the May 27 transaction and 4,274 Restricted Stock Units after the May 28 transaction.
• The RSUs convert to common stock on a one-for-one basis.

Sentiment

Score: 7

Explanation: The document reports routine insider transactions related to executive compensation. The vesting of restricted stock units is a positive sign of continued executive retention and compensation, while the associated tax sales are a standard, non-discretionary event. There are no indications of significant discretionary selling or other negative news.

Positives

• The acquisition of shares through RSU vesting indicates continued compensation and retention of a key executive, Stephen Hoge, as President of Moderna.
• The vesting of RSUs demonstrates the company's commitment to its long-term incentive plans for management.

Negatives

• A portion of the vested shares was sold to cover tax withholding obligations, which reduces the direct beneficial ownership of the executive, though this is a standard practice.

Future Outlook

The remaining unvested restricted stock units are scheduled to vest in twelve equal quarterly installments, indicating future acquisitions of common stock by Stephen Hoge.

Industry Context

Form 4 filings are standard regulatory disclosures for public companies, providing transparency into insider stock transactions. These routine transactions, involving RSU vesting and tax-related sales, are common for executives receiving equity compensation.

Related Party Transactions

• Stephen Hoge indirectly owns 4,116 shares through Valhalla, LLC.
• Stephen Hoge indirectly owns 151,933 shares through a trust for the benefit of his spouse and children, with his spouse as a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders gain transparency into the compensation structure and stock ownership of a key executive, Stephen Hoge.
• The transactions reflect the ongoing equity compensation strategy for company management.

Next Steps

• Future quarterly vesting installments of the remaining restricted stock units for Stephen Hoge.

Key Dates

Recommendation

Keywords

Moderna, MRNA, Stephen Hoge, Form 4, insider transaction, restricted stock units, RSU vesting, executive compensation, stock ownership, tax withholding